Malin Corporation plc (MLC) fair value: what the stock is really worth
As of Oct 23, 2026: fair value (intrinsic value) of Malin Corporation plc stock €13.24, price €6.25, upside +111.8%, quality 73 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range €3.70 – €10.30 · fair‑value band €8.74 – €16.56 · the €6.25 price screens below the €13.24 fair value. Dashed = 300-day average. As of Oct 3, 2026.
Follow Malin Corporation in your weekly email
Every Wednesday you see whether Malin Corporation is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Malin Corporation plc, together with its subsidiaries, operates as an investment company in Europe and North America. It engages in the investment in life sciences and healthcare companies targeting various therapeutic areas, including oncology, immunology, and genetic diseases.
Show moreShow less
The company was incorporated in 2014 and is headquartered in Dublin, Ireland.
Stock analysis
Malin Corporation plc (MLC) currently trades at €6.25, while our model-based Fair Value estimate is €13.24, implying the stock looks roughly 52.8% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the data coverage at low.
Scenario range: €8.74 (bear) to €16.56 (bull), the price of €6.25 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 73/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Malin Corporation plc reported revenue of €0 in FY2024 versus €41.0M in FY2020. Reported net income was €0 in FY2024.
Key figures
Market cap €30.3M Micro · P/S ratio 0.74 · Return on equity −6.0% · Return on assets (EBIT) −1.7% · Revenue (TTM) €41.0M · Revenue growth (YoY) +23.1% · EPS growth (YoY) +13.3% · Free cash flow −€1.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −23% fair-value upside, at 112%, MLC screens cheaper than that median.
Fair Value models
Bear€8.74Fair Value €13.24Bull€16.56
Price €6.25 · Upside +111.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.28/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+17.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
’15
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−117.9% (2015) → −21.7% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 570 stocks
Beats the industry median on 5/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score73 · Top 25%
Fair Value upside+111.8% · Top 25%
Profitability
Return on assets0.0% · Below median
Operating margin (12 months)0.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)23.1% · Top 25%
Balance sheet
Debt / equity0.22× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Malin Corporation plc (MLC) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of €13.24 versus a price of €6.25, about +112% upside (undervalued).
What is the fair value of MLC?
Our model-based fair value for Malin Corporation plc is €13.24 (as of Oct 3, 2026), built from audited fundamentals. The current price: €6.25.
What is the quality score of MLC?
Malin Corporation plc has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Malin Corporation plc (MLC)?
Our model-based price target is the fair value of €13.24 (as of Oct 3, 2026) from 1 valuation models. Cautious scenario €8.74, optimistic scenario €16.56. It is a calculation from audited fundamentals, not an analyst target.
What is the Malin Corporation plc stock forecast for 2026?
Our models put fair value at €13.24, about +112% upside versus a price of €6.25 (undervalued). Cautious scenario €8.74, optimistic scenario €16.56. The calculation is refreshed regularly with new filings.
What is the revenue of Malin Corporation plc (MLC)?
Malin Corporation plc reported trailing-twelve-month revenue of about €41.0M (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Malin Corporation plc (MLC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Malin Corporation plc it is €13.24 per share (as of Oct 3, 2026), against a price of €6.25. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Malin Corporation plc stock overvalued or undervalued in 2026?
As of Oct 3, 2026, MLC trades below its calculated fair value: price €6.25, fair value €13.24, a gap of about +112% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MLC?
No. The price is what the market pays today (€6.25); the fair value is what the company's own numbers justify (€13.24). For Malin Corporation plc the two are €6.99 per share apart. That gap is exactly why we show both numbers side by side.
How much is Malin Corporation plc worth?
The market values Malin Corporation plc at about €30.3M (market capitalisation, as of Oct 3, 2026). Per share that is €6.25; our models calculate a fair value of €13.24 per share.
What do the bullish and bearish scenarios say about MLC?
Our models span a range for Malin Corporation plc: cautious scenario €8.74, base €13.24, optimistic €16.56 per share (as of Oct 3, 2026, price €6.25). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Malin Corporation plc (MLC)?
Balance-sheet figures for Malin Corporation plc (as of Oct 3, 2026): return on equity −6.0%, debt of 0.22 per unit of equity. They feed the Quality Score of 73/100, which measures business quality independently of the share price.
How far is MLC from its 52-week high?
Malin Corporation plc trades at €6.25, about 25% below its 52-week high of €8.30 and at the low of €6.25 (as of Oct 23, 2026). Distance from the high says nothing about value: that is what the fair value of €13.24 is for.
Which stocks are comparable to Malin Corporation plc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Malin Corporation plc stock attractive at the current price?
The data as of Oct 3, 2026: price €6.25, calculated fair value €13.24 (+112%), Quality Score 73/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MLC calculated?
We run Malin Corporation plc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €13.24, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3 % above its aggregate fair value. Malin Corporation plc currently trades 53 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Malin Corporation plc (MLC)?
The closing price on Oct 23, 2026 was €6.25. Our model-based fair value is €13.24, about +112% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Malin Corporation plc right now?
The rarer combination: high quality (73/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (€8.74). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (€8.74 to €16.56) leaves room in how you read the outcome.
Key figures of Malin Corporation plc
How large is the market capitalisation of Malin Corporation plc (MLC)?
The market capitalisation of Malin Corporation plc is €30.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Malin Corporation plc (MLC)?
The price-to-sales ratio of Malin Corporation plc is 0.74 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Malin Corporation plc (MLC)?
The return on equity (ROE) of Malin Corporation plc is −6.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Malin Corporation plc (MLC)?
On an EBIT basis the return on assets of Malin Corporation plc is −1.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Malin Corporation plc (MLC)?
Revenue at Malin Corporation plc is growing +23.1% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Malin Corporation plc (MLC)?
Earnings per share at Malin Corporation plc are growing +13.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Malin Corporation plc (MLC) generate?
The free cash flow of Malin Corporation plc is −€1.3M (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Malin Corporation plc (MLC) hold?
Malin Corporation plc holds more cash than debt, €32.6M net (fiscal year 2021). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Malin Corporation plc in the live analysis
One click puts Malin Corporation plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 3, 2026